# Xience Versus Synergy in Left Main PCI

Study · id `cardio:ct-nct02303717` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02303717](<https://clinicaltrials.gov/study/NCT02303717>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02303717

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 818 participants.

## Technical summary

Registry record NCT02303717. Randomized; single masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 818 participants (planned count; ClinicalTrials.gov record NCT02303717, source copy `cardio:ctgov-nct02303717-2014-12-01`, retrieved 2026-10-26)
- Start date: 2014-12 (registry gives no type) (ClinicalTrials.gov record NCT02303717, source copy `cardio:ctgov-nct02303717-2014-12-01`, retrieved 2026-10-26)
- Primary completion: 2017-12 (anticipated) (ClinicalTrials.gov record NCT02303717, source copy `cardio:ctgov-nct02303717-2014-12-01`, retrieved 2026-10-26)
- Completion: 2020-12 (anticipated) (ClinicalTrials.gov record NCT02303717, source copy `cardio:ctgov-nct02303717-2014-12-01`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02303717-2014-12-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Xience Versus Synergy in Left Main PCI
- Acronym: IDEAL-LM
- Condition: Coronary Artery Disease
- Intervention (Device): Percutaneous coronary intervention
- Intervention (Drug): Dual antiplatelet therapy
- Lead sponsor: NHS National Waiting Times Centre Board
- Lead sponsor class: OTHER
- Collaborator: Boston Scientific Corporation
- Collaborator class: INDUSTRY
- Collaborator: Venn Life Sciences
- Collaborator class: OTHER
- Collaborator: Cardialysis B.V.
- Collaborator class: INDUSTRY
- Collaborator: Diagram B.V.
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: NHS National Waiting Times Centre Board (`cardio:org-nhs-national-waiting-times-centre-board`)
- Registry lists this organization as a collaborator: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: 7aec4a17e0dc5b63cdcbc81ff656eeedf374ba55ed383f5ccec7a3c1bf7e0a45
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
